Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.

Autor: da Silva EP; Universidade Regional de Blumenau, SC. dredson@terra.com.br, Nader F, Quilici FA, Eisig JN, Zaterka S, Meneghelli U
Jazyk: angličtina
Zdroj: Arquivos de gastroenterologia [Arq Gastroenterol] 2003 Oct-Dec; Vol. 40 (4), pp. 262-7. Date of Electronic Publication: 2004 May 31.
DOI: 10.1590/s0004-28032003000400012
Abstrakt: Background: Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis.
Aim: To evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study.
Material and Methods: Two hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug.
Results: Healing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%).
Conclusion: For the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.
Databáze: MEDLINE